Financial releases

SUCCESS OF THE €4 MILLION CAPITAL INCREASE

Business update November 2018

First-half 2018 results and business update

Strengthening of pharma skills within the Crossject supervisory board

Crossject announces the principle of the free issue and allotment of warrants to the shareholders and new € 2.5 million convertible bond

Business update may 2018

Annual 2017 results and business update

Financial calendar 2018

Free allotment of warrants to the shareholders and issue of a convertible bond

FDA grants orphan-drug designation to ZENEO® Midazolam